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Abstract: BACKGROUND AIMS: Glutamine supplementation has been associated with reduced mortal-
ity, infections and hospital length of stay in critically ill patients and patients undergoing major surgery.
We carried out a meta-analysis to examine randomized clinical trial (RCT)-based evidence of these effects.
METHODS: Based on a systematic database search, RCTs published since 1990 were included if they
evaluated the effect of parenteral glutamine supplementation against a background of parenteral nutri-
tion. Enteral (tube) feeding in a proportion of patients was allowable. Information on RCT methodology,
quality and outcomes was extracted. Random effects meta-analysis followed the DerSimonian-Laird ap-
proach. RESULTS: Forty RCTs were eligible for meta-analysis. Parenteral glutamine supplementation
was associated with a non-significant 11% reduction in short-term mortality (RR = 0.89; 95% CI, 0.77-
1.04). Infections were significantly reduced (RR = 0.83; 95% CI, 0.72-0.95) and length of stay was 2.35
days shorter (95% CI, -3.68 to -1.02) in the glutamine arms. Meta-analysis results were strongly in-
fluenced by one recent trial. An element of publication bias could not be excluded. CONCLUSION:
Parenteral glutamine supplementation in severely ill patients may reduce infections, length of stay and
mortality, but substantial uncertainty remains. Unlike previous meta-analyses, we could not demonstrate
a significant reduction in mortality.
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ICU admission status 
 
Patient group Study Ref. Mor. Inf. LOS Yes Partially Unclear Yes No Reason in absence of explicit information
Surgery O'Riordain 1994 34 x x x Gastrointestinal surgery
Morlion 1998 35 x x x Gastrointestinal surgery
Jacobi 1999 36 x x x Gastrointestinal surgery
Jiang 1999 37 0 x x x x Gastrointestinal surgery
Mertes 2000 56 x x x x
Karwowska 2001 52 0 0 x x x Elective aortic aneurysm repair
Neri 2001 38 0 x x x x Gastrointestinal surgery
Spittler 2001 57 x x x x
Goeters 2002 29 x x x x
Lin 2002 39 0 0 x x Gastrointestinal surgery
Exner 2003 58 0 x x x
Fuentes-Orozco 2004 59 x x x x x
Klek 2005 40 x x x x Gastrointestinal surgery
Yao 2005 41 x x x x Gastrointestinal surgery
Jo 2006 42 x x x x x Gastrointestinal surgery
Estivariz 2008 64 x x x x
Yeh 2008 43 0 x x x x
Asprer 2009 27 x x x
Engel 2009 67 0 x x x x Cardiac surgery with cardiopulmonary 
Fan 2009 44 x x x x Gastrointestinal surgery
Lu 2011 45 x x x Gastrointestinal surgery
Critical illness Griffiths 1997/2002 54,55 x x x x x
De Beaux 1998 53 0 x x x Pancreatitis patients, severe
Wischmeyer 2001 31 x x x x x
Ockenga 2002 32 x x x x x Pancreatitis, partially non-severe
Tjäder 2004 60 x x x
Xian-Li 2004 61 x x x x x Pancreatitis patients, severe
Zhou 2004 62 x x x x Burns patients; burn size raging from 30% to 
50% of total body surface
Sahin 2007 33 x x x x Pancreatitis, partially non-severe
Cai 2008 28 x x x x
Duska 2008 51 x x x
Fuentes-Orozco 2008 65 x x x x x
Mixed Powell-Tuck 1999 46 x x x x x
Déchelotte 2006 63 x x x x x
Pérez-Barcena 2008 66 x x x x x
Pérez-Barcena 2010 68 x x x x
Andrews 2011 10 x x x x x
Cekmen 2011 69 x x x x
Grau 2011 70 x x x x x
Wernerman 2011 30 x x x
ICU admissionEndpoints available Inclusion in sensitivity analysis
 
Table S1: ICU admission status and inclusion in sensitivity analyses where 
only studies of patients admitted to the ICU were retained. Studies where only a 
proportion of patients were admitted to the ICU were excluded in these sensitivity 
analyses. In the absence of explicit information, the criteria described in the main 
article applied; a brief description is provided in the rightmost column. Ref., 
Reference number in main article; Mor., Mortality; Inf., Infection; LOS, Length of Stay; 
ICU, Intensive Care Unit. 
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Figure S1: Forest plot of effect of glutamine supplementation on infections. 
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Patients      
[N] 
Effect on Mortality 







Patients      
[N] 
Effect on Infections 







Patients      
[N] 
Effect on LOS 
[WMD (95% CI), p] 
Glutamine Dosage 
  Low Dose (≤0.20 g/kg BW/day)     
      Surgical 
Critically ill 
Mixed             
  High Dose (>0.20 g/kg BW/day) 
      Surgical 
        Critically ill 




















1.05 (0.87 - 1.27), p=0.615 
0.74 (0.33 - 1.63), p=0.448 
0.88 (0.52 - 1.46), p=0.610 
1.11 (0.90 - 1.38), p=0.326 
0.69 (0.54 - 0.88), p=0.003 
0.44 (0.14 - 1.41), p=0.166 
0.64 (0.45 - 0.92), p=0.017 




















1.00 (0.85 - 1.18), p=0.971 
0.42 (0.15 - 1.18), p=0.099 
0.80 (0.27 – 2.37), p=0.687 
1.03 (0.87 – 1.22), p=0.717 
0.79 (0.67 - 0.93), p=0.006 
0.54 (0.35 - 0.83), p=0.006 
0.83 (0.56 - 1.22), p=0.345 




















-2.20 (-4.89 - 0.50), p=0.111 
-3.42 (-4.97 - -1.88), p=0.000 
-2.94 (-6.26 - 0.38), p=0.082 
4.30 (3.16 - 5.44), p=0.000 
-2.29 (-3.65 - -0.94), p=0.001 
-2.43 (-4.10 - -0.75), p=0.004 
-1.23 (-2.90 - 0.44), p=0.150 
-4.77 (-10.69 - 1.16), p=0.115 
Duration of Administration 
  Short Duration (≤9 days) 
      Surgical 
        Critically ill 
        Mixed             
  Long Duration (>9 days) 
      Surgical 
        Critically ill 




















0.96 (0.81 - 1.13), p=0.600 
1.46 (0.19  - 11.34), p=0.719 
0.71 (0.48 - 1.05), p=0.086 
1.02 (0.85 - 1.23), p=0.836 
0.65 (0.45 - 0.93), p=0.019 
0.57 (0.28 - 1.13), p=0.108 
0.67 (0.43 - 1.14), p=0.148 


















0.93 (0.83 - 1.04), p=0.203 
0.45 (0.27 - 0.76), p=0.003 
1.05 (0.79 - 1.39), p=0.744 
0.95 (0.84 - 1.08), p=0.429 
0.62 (0.42 - 0.93), p=0.020 
0.56 (0.20 - 1.57), p=0.271 




















-2.10 (-3.87 - -0.33), p=0.020 
-2.79 (-4.21 - -1.36), p=0.000 
0.00 (-1.68 - 1.67), p=0.997 
-1.83 (-7.14 - 3.48), p=0.499 
-2.37 (-3.36- -1.39), p=0.000 
-2.34 (-3.91 - -0.78), p=0.003 
-2.33 (-3.77 - -0.90), p=0.001 
-8.20 (-17.05 - 0.65), p=0.069 
Time Delay before Start of Treatment 
  Short delay (≤48 hours) 
      Surgical 
        Critically ill 
        Mixed             
  Long delay (>48 hours) 
      Surgical 
        Critically ill 




















0.66 (0.45 - 0.97), p=0.035 
 
0.68 (0.45 - 1.03), p=0.067 
0.50 (0.15 - 1.64), p=0.252 
0.97 (0.72 - 1.32), p=0.854 
0.16 (0.02 - 1.27), p=0.083 
1.26 (0.31 - 5.23), p=0.744 




















1.00 (0.76 - 1.30), p=0.972 
0.50 (0.12 -2.05), p=0.335 
1.02 (0.76 - 1.30), p=0.879 
 
0.97 (0.85 - 1.11), p=0.678 
0.87 (0.57 -1.30), p=0.487 
3.00 (0.14 - 63.15), p=0.480 




















-3.95 (-7.66 - -0.24), p=0.037 
-6.10 (-9.14 - -3.06), p=0.000 
-2.07 (-6.44 - 2.29), p=0.352 
-8.20 (-17.05 - 0.65), p=0.069 
-1.78 (-8.62 - 5.07), p=0.611 
 
 
-1.78 (-8.62 - 5.07), p=0.611 
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Patients      
[N] 
Effect on Mortality 







Patients      
[N] 
Effect on Infections 







Patients      
[N] 
Effect on LOS 
[WMD (95% CI), p] 
Study Quality 
  Low Quality (≤3.5 pointsa) 
      Surgical 
        Critically ill 
        Mixed             
  High Quality (>3.5 pointsa) 
      Surgical 
        Critically ill 




















0.79 (0.53 - 1.16), p=0.221 
0.75 (0.35 - 1.61), p=0.460 
0.72 (0.44 - 1.16), p=0.176 
1.85 (0.37 - 9.12), p=0.452 
0.85 (0.69 - 1.04), p=0.117 
0.37 (0.10 - 1.39), p=0.139 
0.71 (0.49 - 1.03), p=0.072 




















0.68 (0.50 - 0.93), p=0.015 
0.48 (0.29 - 0.81), p=0.005 
0.65 (0.14 - 3.03), p=0.585 
0.85 (0.59 - 1.22), p=0.368 
0.87 (0.74 - 1.02), p=0.080 
0.49 (0.23 - 1.06), p=0.071 
0.87 (0.63 - 1.20), p=0.394 




















-3.42 (-4.68 - -2.17), p=0.000 
-3.18 ( -4.63 - -1.73), p=0.000 
-2.35 (-3.71 - -0.99), p=0.001 
-14.63 (-20.93 - -8.32), p=0.000 
-0.44 (-2.69 - 1.80), p=0.700 
-1.68 (-3.50 - 0.13), p=0.069 
-0.40 (-2.66 - 1.87), p=0.731 
0.25 (-4.69 - 5.18), p=0.923 
Disease Severity 
  Lower Severity (bg mortality ≤0.20) 
      Surgical 
        Critically ill 
        Mixed             
  Higher Severity (bg mortality >0.20) 
      Surgical 
        Critically ill 


















0.77 (0.48 - 1.24), p=0.282 
0.54 (0.18 - 1.62), p=0.274 
0.64 (0.08 - 5.31), p=0.678 
0.86 (0.49 - 1.50), p=0.592 
0.87 (0.72 - 1.04), p=0.126 
0.67 (0.30 - 1.53), p=0.347 
0.71 (0.53 - 0.96), p=0.028 




















0.69 (0.52 - 0.94), p=0.017 
0.48 (0.22 - 1.06), p=0.069 
0.65 (0.14 - 3.03), p=0.585 
0.77 (0.59 - 1.01), p=0.056 
0.99 (0.87 - 1.11), p=0.820 
 
0.86 (0.58 - 1.27), p=0.448 




















-3.77 (-5.24 - -2.30), p=0.000 
-3.08 (-4.10 - -2.05), p=0.000 
-4.32 (-7.39 - -1.25), p=0.006 
-14.26 (-20.51 - -8.02), p=0.000 
0.07 (-2.54 - 2.68), p=0.956 
6.60 (-13.10 - 26.30), p=0.511 
-0.93 (-2.14 - 0.272), p=0.129 
0.19 (-4.81 - 5.20), p=0.940 
 
Table S2: Subgroup analyses by patient type. Bg mortality, background mortality risk defined as the risk of death in the control group; BW, 
body weight; LOS, length of stay; WMD, weighted mean difference; a Score points ascribed to the studies in the quality assessment 
























Multivariate meta-regression analysis – short-term mortality 
 
Meta-regression                                       Number of obs  =      22 
REML estimate of between-study variance               tau2           =       0 
% residual variation due to heterogeneity             I-squared_res  =   0.00% 
Proportion of between-study variance explained        Adj R-squared  = 100.00% 
Joint test for all covariates                         Model F(2,19)  =    5.79 
With Knapp-Hartung modification                       Prob > F       =  0.0109 
------------------------------------------------------------------------------- 
       logrr  |      Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval] 
-------------+----------------------------------------------------------------- 
 High Gln Dose|  -.4480297   .1592667    -2.81   0.011    -.7813788   -.1146807 
Long Duration |  -.4324095   .2040148    -2.12   0.047    -.8594173   -.0054017 
      Constant|   .1344956    .106165     1.27   0.221    -.0877102    .3567014 
------------------------------------------------------------------------------- 
 
Table S3: Multivariate meta-regression model for RR of short-term mortality. 
Adj., adjusted; Coef., coefficient; Conf., confidence; High gln dose, glutamine dose 
>0.20 g/kg body weight/day; I-squared_res, residual I2; Log RR, logarithm of relative 
risk; Long admin., duration of administration >9 days; obs, observations; REML, 
restricted maximum likelihood; Std. Err., standard error; t, t statistic. NOTE: N 




Multivariate meta-regression analysis – hospital length of stay 
 
Meta-regression                                           Number of obs  =      22 
REML estimate of between-study variance                   tau2           =   4.053 
% residual variation due to heterogeneity                 I-squared_res  =  60.22% 
Proportion of between-study variance explained            Adj R-squared  =  62.70% 
Joint test for all covariates                             Model F(3,18)  =    5.86 
With Knapp-Hartung modification                           Prob > F       =  0.0056 
---------------------------------------------------------------------------------- 
          MDLOS  |      Coef.   Std. Err.      t    P>|t|    [95% Conf. Interval] 
----------------+----------------------------------------------------------------- 
    High Gln Dose|  -3.216805   1.412193    -2.28   0.035    -6.183713   -.2498967 
     High Quality|   3.691031   1.607237     2.30   0.034     .3143526     7.06771 
High Disease Sev.|   2.763086   1.467469     1.88   0.076    -.3199523    5.846125 
         Constant|  -3.114436   1.075951    -2.89   0.010    -5.374924   -.8539469 
---------------------------------------------------------------------------------- 
 
Table S4: Multivariate meta-regression model for weighted mean difference of 
hospital length of stay. Adj., adjusted; Coef., coefficient; Conf., confidence; High 
gln dose, glutamine dose >0.20 g/kg body weight/day; High qual. study, high quality 
study (see legend to Table S1); I-squared_res, residual I2; obs, observations; REML, 
restricted maximum likelihood; Sev. disease, higher disease severity (background 
mortality >0.20); Std. Err., standard error; t, t statistic; WMD, weighted mean 
difference. NOTE: N influenced by availability of covariate information.
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Risk of Bias Across Studies 
                                   
                               
 
Figure S3: Funnel plots of short-term mortality, 6-month mortality, infectious complications and LOS. SE, standard error; WMD, 
weighted mean difference. 
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